AlzeCure Pharma AB (AC6) Price & Analysis

3 Followers

AC6 Stock Chart & Stats

€0.15

>-€0.01(-7.07%)

At close: Jan 08 4:00 PM EST

€0.15

>-€0.01(-7.07%)

Day’s Range― - ―

52-Week Range€0.07 - €0.74

Previous CloseN/A

Volume0.00

Average Volume (3M)259.00

Market Cap

€90.34M

Enterprise Value€522.18

Total Cash (Recent Filing)€32.97M

Total Debt (Recent Filing)€2.29M

Price to Earnings (P/E)50.0

Beta-0.22

Next Earnings

Nov 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding137,897,340

10 Day Avg. Volume100

30 Day Avg. Volume259

Financial Highlights & Ratios

PEG Ratio-1.96

Price to Book (P/B)6.11

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.03

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Financial LeverageDebt remains modest relative to the stated equity base, which limits direct balance-sheet leverage and interest-related pressure. This gives AlzeCure comparatively more flexibility to direct resources toward research programs and manage financing decisions while advancing its pipeline.

Proprietary CNS Drug PipelineA proprietary small-molecule pipeline focused on major central nervous system diseases gives the company identifiable scientific assets and a defined therapeutic strategy. Progress in these programs could create opportunities for partnering, licensing, or later commercialization if development succeeds.

Partnering-based Monetization PathwayThe stated partnering model can provide a route to monetize research assets without requiring AlzeCure to independently fund every late-stage development and commercial activity. Successful partnerships could potentially generate upfront, milestone, and royalty income as programs advance.

Bears Say

No Commercial RevenueThe absence of reported revenue means the company has not yet established a commercial income stream to support its research organization. Financial progress therefore remains dependent on successful clinical development, future partnerships, or other funding rather than recurring product sales.

Persistent And Widening LossesLarge recurring operating losses indicate that development spending is not currently covered by operating income. The widening loss profile raises the hurdle for achieving sustainability and may require continued capital support while the company advances candidates through development.

Heavy Cash Burn And Funding DependenceSubstantial negative operating and free cash flow shows that the business consumes cash as it funds research and development. Continued burn implies ongoing financing needs and can constrain strategic flexibility if partnering proceeds or other capital sources do not offset expenditures.

AC6 FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?

AlzeCure Pharma AB lowest stock price was €0.07 and its highest was €0.74 in the past 12 months.

What is AlzeCure Pharma AB’s market cap?

AlzeCure Pharma AB’s market cap is €90.34M.

When is AlzeCure Pharma AB’s upcoming earnings report date?

AlzeCure Pharma AB’s upcoming earnings report date is Nov 11, 2026 which is in 40 days.

How were AlzeCure Pharma AB’s earnings last quarter?

AlzeCure Pharma AB released its earnings results on Aug 26, 2026. The company reported €0.051 earnings per share for the quarter.

Is AlzeCure Pharma AB overvalued?

According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AlzeCure Pharma AB pay dividends?

AlzeCure Pharma AB does not currently pay dividends.

What is AlzeCure Pharma AB’s EPS estimate?

AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AlzeCure Pharma AB have?

AlzeCure Pharma AB has 137,897,340 shares outstanding.

What happened to AlzeCure Pharma AB’s price movement after its last earnings report?

AlzeCure Pharma AB reported an EPS of €0.051 in its last earnings report. Following the earnings report the stock price went up 3.065%.

Which hedge fund is a major shareholder of AlzeCure Pharma AB?

Currently, no hedge funds are holding shares in DE:AC6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AlzeCure Pharma AB

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.